DAIICHI SANKYO COMPANY, LIMITED FY2025 Q3 Financial Results Presentation

Koji Ogawa
Senior Executive Officer, Head of Global Corporate Planning & Management, CFO
Yuki Abe
Corporate Officer, Head of R&D division
Ken Keller
Board of Director, Head of Global Oncology Business

PLAY LIST

from the beginning

FY2025 Q3 Financial Results Presentation

Forward-Looking Statements

1 FY2025 Q3 Financial Results

Overview of FY2025 Q3 Results

Core Operating Profit

Profit Attributable to Owners of the Company

2 Business Update

ENHERTU Performance

DATROWAY Performance

Update on SeagenU.S. Patent Dispute Related to Daiichi Sankyo ADC

The 6th5-year Business Plan Briefing

3 R&D Update

5DXd ADCs Update

Establishing a New 1L Treatment for HER2+ Breast Cancer

Final Analysis for 2L Treatment in HER2+ Breast Cancer

Regulatory Updates

Clinical Trial Progress Updates

Paving the Way for the New 1L SOC in mTNBC

Development in Lung Cancer with Biomarker

Clinical Development Plan Updates

Next Wave Update

Clinical DevelopmentProgress

Award winning of the First Dual EZH1/2 Inhibitor

Q&A 1

Q&A 2

Q&A 3

Q&A 4

Q&A 5

Q&A 6

Q&A 7

Q&A 8

Q&A 9

Back
Next

Download

Presentation File(PDF 2.8 MB)